Search

Your search keyword '"Le Gouill S"' showing total 593 results
Start Over Author "Le Gouill S"
593 results on '"Le Gouill S"'

5. ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) GRADE 1–3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE II STUDY ELM‐2

Author

Novelli, S., primary, Luminari, S., additional, Taszner, M., additional, Cho, S., additional, Le Gouill, S., additional, Poon, M., additional, Villasboas, J. C., additional, Champion, R., additional, Bachy, E., additional, Guidez, S., additional, Alonso, A., additional, Jagadeesh, D., additional, Merli, M., additional, Tucker, D., additional, Cai, J., additional, Leite de Oliveira, C., additional, Zhu, M., additional, Chaudhry, A., additional, Mohamed, H., additional, Ambati, S., additional, and Kim, T. M., additional

Published
2023
Full Text
View/download PDF

6. Efficacy of anti‐PD1 therapy in relapsed or refractory NK/T cell lymphoma: a matched cohort analysis from the LYSA

Author

Marouf, A., primary, Chaubard, S., additional, Michot, J., additional, Liévin, R., additional, Rossignol, J., additional, Golfier, C., additional, Allangba, O., additional, Philippe, L., additional, Tessoulin, B., additional, Chauchet, A., additional, Deau, B., additional, Oberic, L., additional, Vargaftig, J., additional, Moignet, A., additional, Clavert, A., additional, Dulery, R., additional, Brisou, G., additional, Tardy, S., additional, Fataccioli, V., additional, Houot, R., additional, Casasnovas, R., additional, Thieblemont, C., additional, Ghesquières, H., additional, Carras, S., additional, Le Gouill, S., additional, Cartron, G., additional, Marabelle, A., additional, Tournilhac, O., additional, Damaj, G., additional, Gaulard, P., additional, De Leval, L., additional, Lemonnier, F., additional, Bachy, E., additional, Hermine, O., additional, Couronné, L., additional, and Jaccard, A., additional

Published
2023
Full Text
View/download PDF

8. VERY LONG‐TERM FOLLOW‐UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY.

Author

Sarkozy, C., primary, Thieblemont, C., additional, Oberic, L., additional, Moreau, A., additional, Bouabdallah, K., additional, Damaj, G., additional, Gastine, T., additional, Ribrag, V., additional, Casasnovas, O., additional, Haioun, C., additional, Houot, R., additional, Jardin, F., additional, Van Den Neste, E., additional, Cheminant, M., additional, Morschhauser, F., additional, Callana, M., additional, Ghesquieres, H., additional, Gressin, R., additional, Hermine, O., additional, and Le Gouill, S., additional

Published
2023
Full Text
View/download PDF

11. Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party

Author

Bento, L, Boumendil, A, Finel, H, Le Gouill, S, Amorim, S, Monjanel, H, Bouabdallah, R, Bay, J O, Nicolas-Virelizier, E, McQuaker, G, Rossi, G, Johnson, R, Huynh, A, Ceballos, P, Rambaldi, A, Bachy, E, Malladi, R, Orchard, K, Pohlreich, D, Tilly, H, Bonifazi, F, Poiré, X, Guilhot, F, Haenel, A, Crawley, C, Metzner, B, Gribben, J, Russell, N H, Damaj, G, Thomson, K, Dreger, P, and Montoto, S

Published
2017
Full Text
View/download PDF

15. Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC

Author

Tessoulin, B, Ceballos, P, Chevallier, P, Blaise, D, Tournilhac, O, Gauthier, J, Maillard, N, Tabrizi, R, Choquet, S, Carras, S, Ifrah, N, Guillerm, G, Mohty, M, Tilly, H, Socie, G, Cornillon, J, Hermine, O, Daguindau, É, Bachy, E, Girault, S, Marchand, T, Oberic, L, Reman, O, Leux, C, and Le Gouill, S

Published
2016
Full Text
View/download PDF

16. Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience

Author

Bourcier, J., Gastinne, T., Leux, C., Moreau, A., Bossard, C., Mahé, B., Blin, N., Dubruille, V., Touzeau, C., Voldoire, M., Guillaume, T., Peterlin, P., Gallas, P., Garnier, A., Maisonneuve, H., Moreau, P., Juge-Morineau, N., Jardel, H., Chevallier, P., Moreau, P., and Le Gouill, S.

Published
2016
Full Text
View/download PDF

22. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

Author

Bishop, M. R., Dickinson, M., Purtill, D., Barba, P., Santoro, A., Hamad, N., Kato, K., Sureda, A., Greil, R., Thieblemont, C., Morschhauser, F., Janz, M., Flinn, I, Rabitsch, W., Kwong, Y-L, Kersten, M. J., Minnema, M. C., Holte, H., Chan, E. H. L., Martinez-Lopez, J., Mueller, A. M. S., Maziarz, R. T., McGuirk, J. P., Bachy, E., Le Gouill, S., Dreyling, M., Harigae, H., Bond, D., Andreadis, C., McSweeney, P., Kharfan-Dabaja, M., Newsome, S., Degtyarev, E., Awasthi, R., del Corral, C., Andreola, G., Masood, A., Schuster, S. J., Jaeger, U., Borchmann, P., Westin, J. R., Bishop, M. R., Dickinson, M., Purtill, D., Barba, P., Santoro, A., Hamad, N., Kato, K., Sureda, A., Greil, R., Thieblemont, C., Morschhauser, F., Janz, M., Flinn, I, Rabitsch, W., Kwong, Y-L, Kersten, M. J., Minnema, M. C., Holte, H., Chan, E. H. L., Martinez-Lopez, J., Mueller, A. M. S., Maziarz, R. T., McGuirk, J. P., Bachy, E., Le Gouill, S., Dreyling, M., Harigae, H., Bond, D., Andreadis, C., McSweeney, P., Kharfan-Dabaja, M., Newsome, S., Degtyarev, E., Awasthi, R., del Corral, C., Andreola, G., Masood, A., Schuster, S. J., Jaeger, U., Borchmann, P., and Westin, J. R.

Abstract

BACKGROUND Patient outcomes are poor for aggressive B-cell non-Hodgkin's lymphomas not responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an anti-CD19 chimeric antigen receptor T-cell therapy approved for diffuse large B-cell lymphoma after at least two treatment lines. METHODS We conducted an international phase 3 trial involving patients with aggressive lymphoma that was refractory to or progressing within 12 months after first-line therapy. Patients were randomly assigned to receive tisagenlecleucel with optional bridging therapy (tisagenlecleucel group) or salvage chemotherapy and autologous hematopoietic stem-cell transplantation (HSCT) (standard-care group). The primary end point was event-free survival, defined as the time from randomization to stable or progressive disease at or after the week 12 assessment or death. Crossover to receive tisagenlecleucel was allowed if a defined event occurred at or after the week 12 assessment. Other end points included response and safety. RESULTS A total of 322 patients underwent randomization. At baseline, the percentage of patients with high-grade lymphomas was higher in the tisagenlecleucel group than in the standard-care group (24.1% vs. 16.9%), as was the percentage with an International Prognostic Index score (range, 0 to 5, with higher scores indicating a worse prognosis) of 2 or higher (65.4% vs. 57.5%). A total of 95.7% of the patients in the tisagenlecleucel group received tisagenlecleucel; 32.5% of the patients in the standard-care group received autologous HSCT. The median time from leukapheresis to tisagenlecleucel infusion was 52 days. A total of 25.9% of the patients in the tisagenlecleucel group had lymphoma progression at week 6, as compared with 13.8% of those in the standard-care group. The median event-free survival in both groups was 3.0 months (hazard ratio for event or death in the tisagenlecleucel group, 1.07; 95% confidence interval, 0.82 to 1.40; P=0.61).

Published
2022

25. S210: CAR T-CELLS ASSOCIATED ACUTE TOXICITY IN B-CELL NON-HODGKIN LYMPHOMA: REAL-WORLD STUDY FROM THE DESCAR-T REGISTRY

Author

SESQUES, P., primary, DI BLASI, R., additional, LE GOUILL, S., additional, CARTRON, G., additional, MANSON, G., additional, BEAUVAIS, D., additional, LE BRAS, F., additional, GROS, F. X., additional, CHOQUET, S., additional, BORIES, P., additional, RUBIO, M. T., additional, CASASNOVAS, R. O., additional, BOUNAIX, L., additional, MOHTY, M., additional, JORIS, M., additional, ABRAHAM, J., additional, CASTILLA LLORENTE, C., additional, LOSCHI, M., additional, CARRAS, S., additional, CHAUCHET, A., additional, DRIEU LA ROCHELLE, L., additional, ZERBIT, J., additional, HERMINE, O., additional, GUIDEZ, S., additional, GASTINNE, T., additional, TUDESQ, J. J., additional, FOGARTY, P., additional, BROUSSAIS, F., additional, MORSCHHAUSER, F., additional, HOUOT, R., additional, THIEBLEMONT, C., additional, and BACHY, E., additional

Published
2022
Full Text
View/download PDF

26. S209: PRIMARY RESULTS FROM THE PHASE 3 SHINE STUDY OF IBRUTINIB IN COMBINATION WITH BENDAMUSTINE-RITUXIMAB (BR) AND R MAINTENANCE AS A FIRST-LINE TREATMENT FOR OLDER PATIENTS WITH MANTLE-CELL LYMPHOMA

Author

Wang, M. L., primary, Jurczak, W., additional, Jerkeman, M., additional, Trotman, J., additional, Zinani, P. L., additional, Belada, D., additional, Boccomini, C., additional, Flinn, I. W., additional, Giri, P., additional, Goy, A., additional, Hamlin, P. A., additional, Hermine, O., additional, Hernández-Rivas, J.-Á., additional, Hong, X., additional, Kim, S. J., additional, Lewis, D., additional, Mishima, Y., additional, Özcan, M., additional, Perini, G. F., additional, Pocock, C., additional, Song, Y., additional, Spurgeon, S. E., additional, Storring, J. M., additional, Walewski, J., additional, Zhu, J., additional, Qin, R., additional, Henninger, T., additional, Deshpande, S., additional, Howes, A., additional, Le Gouill, S., additional, and Dreyling, M., additional

Published
2022
Full Text
View/download PDF

27. P683: A FIRST-IN-HUMAN PHASE 1 STUDY OF ORAL LOXO-338, A SELECTIVE BCL2 INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES (TRIAL IN PROGRESS)

Author

Jurczak, W., primary, Alencar, A. J., additional, Guru Murthy, G. S., additional, Hoffmann, M., additional, Pagel, J. M., additional, Patel, V., additional, Pauff, J. M., additional, Zinzani, P. L., additional, Le Gouill, S., additional, Mato, A. R., additional, and Roeker, L. E., additional

Published
2022
Full Text
View/download PDF

28. S260: A MATCHED COMPARISON OF TISAGENLECLEUCEL AND AXICABTAGENE CILOLEUCEL CAR T CELLS IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-LIFE LYSA STUDY FROM THE FRENCH DESCAR-T REGISTRY

Author

Bachy, E., primary, Le Gouill, S., additional, Sesques, P., additional, Di Blasi, R., additional, Guillaume, M., additional, Cartron, G., additional, Beauvais, D., additional, Roulin, L., additional, Gros, F. X., additional, Rubio, M. T., additional, Bories, P., additional, Bay, J. O., additional, Castilla Llorente, C., additional, Choquet, S., additional, Casasnovas, R.-O., additional, Mothy, M., additional, Guidez, S., additional, Joris, M., additional, Loschi, M., additional, Carras, S., additional, Abraham, J., additional, Chauchet, A., additional, Drieu La Rochelle, L., additional, Zerbit, J., additional, Hermine, O., additional, Gastinne, T., additional, Tudesq, J. J., additional, Gat, E., additional, Broussais, F., additional, Thieblemont, C., additional, Houot, R., additional, and Morschhauser, F., additional

Published
2022
Full Text
View/download PDF

29. P1100: BRUIN MCL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED, BTK INHIBITOR NAÏVE MCL (TRIAL IN PROGRESS)

Author

Eyre, T. A., primary, Shah, N. N., additional, Le Gouill, S., additional, Dreyling, M., additional, Vandenberghe, E., additional, Jurczak, W., additional, Wang, Y., additional, Cheah, C. Y., additional, Gandhi, M., additional, Chay, C., additional, Sharman, J. P., additional, Andorsky, D. J., additional, Yin, M., additional, Balbas, M., additional, Kherani, J., additional, and Wang, M. L., additional

Published
2022
Full Text
View/download PDF

30. P1131: POST HOC ANALYSIS OF PATIENTS WITH HIGHLY PROLIFERATIVE VARIANTS OF MANTLE CELL LYMPHOMA TREATED WITH ACALABRUTINIB

Author

Le Gouill, S., primary, Długosz-Danecka, M., additional, Rule, S., additional, Luigi Zinzani, P., additional, Goy, A., additional, Smith, S. D., additional, Doorduijn, J. K., additional, Panizo, C., additional, Shah, B., additional, Davies, A., additional, Eek, R., additional, Jacobsen, E., additional, Kater, A. P., additional, Robak, T., additional, Jain, P., additional, Calvo, R., additional, Yang, H., additional, and Wang, M., additional

Published
2022
Full Text
View/download PDF

31. P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY

Author

Eyre, T. A., primary, Wang, M. L., additional, Shah, N. N., additional, Alencar, A. J., additional, Gerson, J. N., additional, Patel, M. R., additional, Fakhri, B., additional, Vandenberghe, E., additional, Jurczak, W., additional, Tan, X. N., additional, Lewis, K. L., additional, Fenske, T., additional, Wang, Y., additional, Coombs, C. C., additional, Flinn, I., additional, Lewis, D., additional, Le Gouill, S., additional, Gandhi, M., additional, Chay, C., additional, Palomba, M. L., additional, Woyach, J. A., additional, Pagel, J. M., additional, Lamanna, N., additional, Sharman, J. P., additional, Andorsky, D. J., additional, Cohen, J. B., additional, Barve, M. A., additional, Ghia, P., additional, Yin, M., additional, Zinzani, P. L., additional, Ujjani, C., additional, Koh, Y., additional, Izutsu, K., additional, Lech-Maranda, E., additional, Kherani, J., additional, Tam, C., additional, Sundaram, S., additional, Nair, B., additional, Tsai, D. E., additional, Balbas, M., additional, Mato, A. R., additional, and Cheah, C. Y., additional

Published
2022
Full Text
View/download PDF

32. P1186: A LARGE FRENCH REAL WORLD MULTICENTRIC PROSPECTIVE COHORT OF PATIENTS WITH LYMPHOMA (REALYSA STUDY): DESCRIPTION OF THE DIFFUSE LARGE B CELL LYMPHOMA PATIENTS IN REAL WORLD IN FRANCE

Author

Ghesquieres, H., primary, Cherblanc, F., additional, Belot, A., additional, Camus, V., additional, Thokagevistk, K., additional, Bouabdallah, K.-K., additional, Esnault, C., additional, Fornecker, L.-M., additional, Micon, S., additional, Bijou, F., additional, Haioun, C., additional, Morineau, N., additional, Ysebaert, L., additional, Damaj, G., additional, Le Gouill, S., additional, Guidez, S., additional, Morschhauser, F., additional, Thiéblemont, C., additional, Chauchet, A., additional, Gressin, R., additional, Jardin, F., additional, Fruchart, C., additional, Labouré, G., additional, Fouillet, L., additional, Lionne-Huyghe, P., additional, Bonnet, A., additional, Lebras, L., additional, Amorim, S., additional, Leyronnas, C., additional, Olivier, G., additional, Guieze, R., additional, Lamy, T., additional, Launay, V., additional, Drenou, B., additional, Fitoussi, O., additional, Detourmignies, L., additional, Abraham, J., additional, Soussain, C., additional, Lachenal, F., additional, Fogarty, P., additional, Cony-Makhoul, P., additional, Bernier, A., additional, Le Guyader-Peyrou, S., additional, Monnereau, A., additional, Boissard, F., additional, and Rossi, C., additional

Published
2022
Full Text
View/download PDF

36. P56 - Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation -Bridging to transplantation: COMPARABLE OUTCOMES AMONG ADULT PATIENTS ALLOTRANSPLANTED FOR MYELODYSPLASTIC SYNDROME USING HAPLOIDENTICAL, MATCHED UNRELATED OR MATCHED SIBLING DONORS: A SINGLE-CENTER STUDY.

Author

Garnier, A., Jullien, M., Guillaume, T., Peterlin, P., Le Bourgeois, A., Mahe, B., Dubruille, V., Blin, N., Touzeau, C., Gastinne, T., Lok, A., Vantyghem, S., Moreau, P., Bene, M.C., Le Gouill, S., and Chevallier, P.

Published
2021
Full Text
View/download PDF

41. The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT

Author

Robinson, S P, Canals, C, Luang, J J, Tilly, H, Crawley, C, Cahn, J Y, Pohlreich, D, Le Gouill, S, Gilleece, M, Milpied, N, Attal, M, Biron, P, Maury, S, Rambaldi, A, Maertens, J, Capria, S, Colombat, P, Montoto, S, and Sureda, A

Published
2013
Full Text
View/download PDF

42. Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation -Bridging to transplantation

Author

Garnier, A., primary, Jullien, M., additional, Guillaume, T., additional, Peterlin, P., additional, Le Bourgeois, A., additional, Mahe, B., additional, Dubruille, V., additional, Blin, N., additional, Touzeau, C., additional, Gastinne, T., additional, Lok, A., additional, Vantyghem, S., additional, Moreau, P., additional, Bene, M.C., additional, Le Gouill, S., additional, and Chevallier, P., additional

Published
2021
Full Text
View/download PDF

43. Nonclassical Monocytes Are Prone to Migrate Into Tumor in Diffuse Large B-Cell Lymphoma

Author

Casanovas O, Jonathan M. Irish, Thierry Fest, Juliette Ferrant, Kamal Bouabdallah, Mingam A, Le Gallou S, Karin Tarte, Lhomme F, Guillaume Cartron, Imane Azzaoui, Delphine Rossille, Godemer P, Thierry Jo Molina, Céline Pangault, Céline Monvoisin, Ghandi Damaj, Roch Houot, Thierry Lamy, Le Gouill S, Murielle Roussel, Microenvironment, Cell Differentiation, Immunology and Cancer (MICMAC), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Pontchaillou [Rennes], Vanderbilt University School of Medicine [Nashville], CHU Bordeaux [Bordeaux], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre hospitalier Bretagne Atlantique (Morbihan) (CHBA), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), HAL UR1, Admin, and ANR-17-CE15-0015,StroMAC,Cross-talk des macrophages et du stroma au sein du ganglion lymphatique(2017)

Subjects
Adult, Male, [SDV]Life Sciences [q-bio], Immunology, CCL3, Biology, Monocytes, CCL5, Immunophenotyping, immune system diseases, hemic and lymphatic diseases, medicine, Humans, Mass cytometry, Clinical significance, neoplasms, Aged, Original Research, Monocyte, Middle Aged, medicine.disease, Phenotype, Lymphoma, B cell lymphoma, [SDV] Life Sciences [q-bio], medicine.anatomical_structure, DLBCL, monocyte, Cancer research, biomarker, Female, Lymphoma, Large B-Cell, Diffuse, immune suppression, Diffuse large B-cell lymphoma
Abstract

Absolute count of circulating monocytes has been proposed as an independent prognostic factor in diffuse large B-cell lymphoma (DLBCL). However, monocyte nomenclature includes various subsets with pro-, anti-inflammatory, or suppressive functions, and their clinical relevance in DLBCL has been poorly explored. Herein, we broadly assessed circulating monocyte heterogeneity in 91 DLBCL patients. Classical- (cMO, CD14pos CD16neg) and intermediate- (iMO, CD14pos CD16pos) monocytes accumulated in DLBCL peripheral blood and exhibited an inflammatory phenotype. On the opposite, nonclassical monocytes (ncMO, CD14low CD16pos) were decreased in peripheral blood. Tumor-conditioned monocytes presented similarities with ncMO phenotype from DLBCL and were prone to migrate in response to CCL3, CCL5, and CXCL12, and presented similarities with DLBCL-infiltrated myeloid cells, as defined by mass cytometry. Finally, we demonstrated the adverse value of an accumulation of nonclassical monocytes in 2 independent cohorts of DLBCL.Key pointsNonclassical monocytes are prone to migrate to DLBCL tumorHigh count of circulating nonclassical monocytes is an independent adverse event in DLBCL

Published
2021
Full Text
View/download PDF

44. A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma

Author

Dreyling, M, Tam, CS, Wang, M, Smith, SD, Ladetto, M, Huang, H, Novotny, W, Co, M, Romano, A, Holmgren, E, Huang, J, Le Gouill, S, Dreyling, M, Tam, CS, Wang, M, Smith, SD, Ladetto, M, Huang, H, Novotny, W, Co, M, Romano, A, Holmgren, E, Huang, J, and Le Gouill, S

Abstract

Mantle cell lymphoma is an aggressive B-cell malignancy. Current frontline chemoimmunotherapies produce high response rates but relapse is inevitable. Furthermore, the elderly and those with comorbidities are precluded from standard regimens and stem cell transplant, leaving them with limited options. Targeted therapies, including Bruton tyrosine kinase inhibitors, are an effective treatment strategy in mantle cell lymphoma. Zanubrutinib is a potent next-generation Bruton tyrosine kinase inhibitor that has demonstrated complete and sustained Bruton tyrosine kinase occupancy, minimal off-target effects and favorable pharmacokinetic/pharmacodynamic properties. Described herein is an ongoing Phase III study comparing the efficacy and safety of zanubrutinib plus rituximab followed by zanubrutinib monotherapy versus bendamustine plus rituximab followed by observation in transplant-ineligible patients with previously untreated mantle cell lymphoma.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results